Department of Psychiatry and Biobehavioral Sciences, The David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-6968, USA.
Neuropsychopharmacology. 2011 Jun;36(7):1375-84. doi: 10.1038/npp.2011.22. Epub 2011 Mar 9.
Brain iron increases with age and is abnormally elevated early in the disease process in several neurodegenerative disorders that impact memory including Alzheimer's disease (AD). Higher brain iron levels are associated with male gender and presence of highly prevalent allelic variants in genes encoding for iron metabolism proteins (hemochromatosis H63D (HFE H63D) and transferrin C2 (TfC2)). In this study, we examined whether in healthy older individuals memory performance is associated with increased brain iron, and whether gender and gene variant carrier (IRON+) vs noncarrier (IRON-) status (for HFE H63D/TfC2) modify the associations. Tissue iron deposited in ferritin molecules can be measured in vivo with magnetic resonance imaging utilizing the field-dependent relaxation rate increase (FDRI) method. FDRI was assessed in hippocampus, basal ganglia, and white matter, and IRON+ vs IRON- status was determined in a cohort of 63 healthy older individuals. Three cognitive domains were assessed: verbal memory (delayed recall), working memory/attention, and processing speed. Independent of gene status, worse verbal-memory performance was associated with higher hippocampal iron in men (r=-0.50, p=0.003) but not in women. Independent of gender, worse verbal working memory performance was associated with higher basal ganglia iron in IRON- group (r=-0.49, p=0.005) but not in the IRON+ group. Between-group interactions (p=0.006) were noted for both of these associations. No significant associations with white matter or processing speed were observed. The results suggest that in specific subgroups of healthy older individuals, higher accumulations of iron in vulnerable gray matter regions may adversely impact memory functions and could represent a risk factor for accelerated cognitive decline. Combining genetic and MRI biomarkers may provide opportunities to design primary prevention clinical trials that target high-risk groups.
脑铁随年龄增长而增加,在几种影响记忆的神经退行性疾病(包括阿尔茨海默病)的疾病早期异常升高。较高的脑铁水平与男性性别和编码铁代谢蛋白的基因中高度常见的等位基因变异有关(血色病 H63D(HFE H63D)和转铁蛋白 C2(TfC2))。在这项研究中,我们检查了在健康的老年人中,记忆表现是否与脑铁增加有关,以及性别和基因变异携带者(IRON+)与非携带者(IRON-)状态(针对 HFE H63D/TfC2)是否会改变这些关联。可以利用磁共振成像利用场依赖性弛豫率增加(FDRI)方法在体内测量沉积在铁蛋白分子中的组织铁。在 63 名健康老年人的队列中评估了海马体、基底神经节和白质中的 FDRI,并确定了 IRON+与 IRON-状态。评估了三个认知领域:言语记忆(延迟回忆)、工作记忆/注意力和处理速度。无论基因状态如何,男性海马体铁含量较高与言语记忆表现较差(r=-0.50,p=0.003)相关,但女性则无此关联。无论性别如何,IRON-组基底神经节铁含量较高与言语工作记忆表现较差(r=-0.49,p=0.005)相关,但在 IRON+组中则无此关联。这两个关联都注意到了组间相互作用(p=0.006)。未观察到与白质或处理速度的显著关联。结果表明,在特定的健康老年人亚组中,易受影响的灰质区域铁的积累较高可能会对记忆功能产生不利影响,并可能成为加速认知衰退的危险因素。结合遗传和 MRI 生物标志物可能为设计针对高危人群的一级预防临床试验提供机会。